Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients
PLoS ONE, 2022 Background Maintenance drugs are used to treat chronic conditions. Several classes of maintenance drugs have attracted attention because of their potential to affect susceptibility to and severity of COVID-19.
Kin Wah Fung +5 more
doaj +2 more sources
Non-Negative Matrix Factorization for 2D-XAS Images of Lithium Ion Batteries [PDF]
, 2020 Lithium-ion secondary batteries have been used in a wide variety of purposes, such as for powering mobile devices and electric vehicles, but their performance should be improved. One of the factors that limits their performance is the non-uniformity of the chemical reaction in the process of charging and discharging.
arxiv +1 more source
Clinical Pathways and Outcomes of Andexanet Alfa Administration for the Reversal of Critical Bleeding in Patients on Oral Direct Factor Xa Inhibitors. [PDF]
TH OpenBackground Andexanet is U.S. Food and Drug Administration (FDA) approved for the reversal of critical bleeding from factor Xa inhibitors and off-label for surgical reversal. Data are lacking on andexanet administration processes.
Goldin M +16 more
europepmc +2 more sources
Managing patients taking novel oral anticoagulants (NOAs) in dentistry: A discussion paper on clinical implications [PDF]
, 2016 Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors ...
Costantinides, Fulvia +3 more
core +1 more source
TH Open, 2020 Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However, data from randomized trials may not extrapolate to general population. We aimed to
Yimin Pearl Wang +3 more
doaj +1 more source
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant [PDF]
, 2020 One of the most common mutations in the serine protease inhibitor Kazal type 1 (SPINK1) gene is the N34S variant which is strongly associated with chronic pancreatitis. Although it is assumed that N34S mutation constitutes a high-risk factor, the underlying pathologic mechanism is still unknown.
arxiv +1 more source
Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]
, 2016 Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K. +4 more
core +4 more sources
Molecules, 2023 Despite extensive research in the field of thrombotic diseases, the prevention of blood clots remains an important area of study. Therefore, the development of new anticoagulant drugs with better therapeutic profiles and fewer side effects to combat ...
Nadezhda P. Novichikhina +12 more
doaj +1 more source
SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS
Атеротромбоз, 2016 Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban, dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding is no less than 2.3–3.1% per year.
O. O. Shakhmatova
doaj +1 more source